Structural Biology Market Experiencing Rapid Growth

The global structural biology market is expanding rapidly worldwide, and between 2023 and 2032, hundreds of millions of dollars are expected to be generated in revenue altogether. Structural biology plays a pivotal role in understanding the intricate organization of living matter, deciphering the spatial arrangement of atoms and molecules, and elucidating the complex folding patterns of biopolymers.

Structural Biology Market Size 2023 To 2032

Market Overview

The structural biology market is experiencing rapid growth, driven by its crucial role in studying the molecular structures of living matter, including proteins, nucleic acids, lipid membranes, and carbohydrates. This field provides essential insights into biomolecule function, dynamics, and interactions, employing techniques like X-ray crystallography, nuclear magnetic resonance spectroscopy, cryo-electron microscopy, and computer modeling to determine 3D structures at the atomic level. The information garnered from structural biology research extends far beyond its own realm, finding applications in medicine, biotechnology, and agriculture. Understanding the 3D structure of biological macromolecules is pivotal for elucidating their functions, roles in cellular processes, disease mechanisms, and aiding drug discovery.

Get report sample pages@ https://www.precedenceresearch.com/sample/3226

Technological advancements have propelled the field forward, with over 206,000 structures of biological macromolecules experimentally determined to date. Innovations in instrumentation, analytical software, and automation, alongside access to high-brilliance synchrotron radiation and X-Ray Free-Electron Laser sources, have facilitated high-quality experiments and time-resolved studies. New magnet technology has enhanced signal-to-noise ratios, enabling the study of large systems and time-resolved structural investigations.

Key Insights

  • North America is projected to have a highest market share during the forecast period.
  • By Tools, the SaaS and standalone modeling segment is expected to captured the biggest revenue share over the forecast period.
  • By Application, the drug discovery segment is expected to captured the maximum market share during the forecast period.

Get full access of this report@ https://www.precedenceresearch.com/checkout/3226

Regional Stance

North America is poised to maintain its dominance in the structural biology market throughout the forecast period. In the United States, significant research efforts within the Department of Structural Biology, particularly at institutions like Stanford Medicine, are dedicated to addressing structural challenges related to biological molecules. Employing advanced biophysical methodologies such as X-ray crystallography, electron crystallography, NMR spectroscopy, and computational analysis, researchers are advancing our understanding of complex biological systems.

  • The New York Structural Biology Center (NYSBC) stands as a prominent collaboration focused on providing cutting-edge resources in structural biology. Located in Harlem, its main facility houses state-of-the-art instrumentation including nuclear magnetic resonance spectroscopy and cryoelectron microscopy, enabling high-quality research and analysis. NYSBC's partnership with the National Synchrotron Light Source NSLS-2 at Brookhaven National Laboratory further enhances its capabilities with the development of NYX, a new beamline tailored to leverage NSLS-2's brightness.

Canada's contributions to structural biology are notable, with initiatives like the Canada Research Chair in Structural Biology conducting groundbreaking research. This includes investigations into bacterial kinases involved in stress response and human atypical kinases, shedding light on crucial biological mechanisms.

  • In January 2023, Amgen announced that AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), was now available in the United States
  • In March 2023, NVIDIA unveiled large language models and generative AI service to advance life sciences R&D.
  • In March 2023, Dupixent demonstrated the potential to become the first biologic to treat COPD by showing a significant reduction in exacerbations in a pivotal trial.

Asia Pacific is anticipated to exhibit the highest compound annual growth rate (CAGR) in the structural biology market during the forecast period. The Asia Pacific Bioinformatics Network plays a pivotal role in advancing bioinformatics research and education across the region. Through training programs, workshops, symposia, and collaborations, the network fosters innovation and knowledge exchange among bioinformatics professionals and policymakers.

In India, significant strides have been made in the field of structural biology, with a promising trajectory towards endeavors such as inhibitor (drug) design. The country's achievements in structural biology are noteworthy, with ongoing efforts aimed at further advancement. Indian researchers are on the brink of gaining access to four Cryogenic-Electron Microscopy (Cryo-EM) facilities, which will bolster leadership in structural biology, enzymology, and drug discovery to address emerging diseases.

  • In June 2023, Inventia continued its global expansion into the Indian market through a distribution agreement for RASTRUM with Biotron Healthcare PVT Ltd.
  • In November 2023, Elsevier partnered with the Korean Society for Molecular and Cellular Biology to publish molecules and cells.

Report Highlights                                      

By Tools

The SaaS and standalone modeling segment is projected to lead the market in terms of tools utilization during the forecast period. e-SC is a key player in this segment, offering both Software as a Service (SaaS) and Platform as a Service (PaaS) solutions tailored for scientific data management, analysis, and collaboration. Notably, e-SC's platform is highly adaptable, capable of deployment on both private (e.g., Eucalyptus) and public clouds (such as Amazon AWS and Microsoft Windows Azure), ensuring accessibility and flexibility for users.

The SaaS application provided by e-SC streamlines scientific workflows by empowering scientists to effortlessly upload, modify, and execute tasks directly through a web browser. This cloud-based approach enables seamless collaboration and data sharing among researchers, enhancing productivity and efficiency. Supported by a scalable cloud infrastructure, e-SC's platform comprises a comprehensive suite of components meticulously designed to meet the diverse needs of scientists. Additionally, the platform is developer-friendly, allowing for easy integration of custom analysis services, thereby extending its functionality and utility to users. Traditional practices have involved deploying models on a standalone basis, typically utilizing command line interfaces and Jupyter notebooks. These models were often simpler in nature and lacked real-time interaction with data sources or software applications. Typically confined to specific business units or functional groups, companies relied on data scientists to oversee the entire lifecycle of model development, from scoping and design to deployment and maintenance.

This transitional phase has been pivotal for companies to validate the effectiveness of AI/ML models and navigate the challenges associated with broader adoption. By embracing cloud-based SaaS solutions like e-SC, organizations can unlock enhanced collaboration, scalability, and efficiency in their scientific endeavors, driving innovation and driving growth in the market.

By Application

The global structural biology market is segmented into various applications, including drug development, drug discovery, and others. Integrative structural biology plays a pivotal role in converting structural information into valuable chemical knowledge, thereby facilitating the expedited delivery of drugs to the clinic. Proteins, nucleic acids, and their complexes constitute a significant portion of drug targets, underscoring the importance of understanding their structural characteristics.

The rational identification, design, and optimization of drug-lead compounds hinge upon a deep understanding of the atomic interactions between the target biomolecules and the investigational small-molecule ligands. Structural biology, particularly the elucidation of 3D protein structures, holds immense potential in accelerating drug discovery efforts. Recent advancements in genome sequencing, robotics, and bioinformatics have revolutionized the landscape, leading to the identification of numerous new protein targets.

Structural biology techniques, such as X-ray crystallography and NMR spectroscopy, have been instrumental in studying these targets and guiding lead optimization, target identification, and lead discovery processes. The advent of high-throughput methods for structure determination has further empowered researchers, offering powerful screening approaches. Among these techniques, macromolecular X-ray crystallography has traditionally been the preferred method for structure-based lead drug discovery (SBLDD). However, Cryo-EM has emerged as a promising addition to the structural biology toolbox, providing researchers with enhanced capabilities for visualizing complex biomolecular structures. As such, the integration of structural biology methodologies into drug development and discovery workflows is expected to drive innovation and accelerate therapeutic advancements in the pharmaceutical industry.

Market Dynamics

Driver

Structural Biology Through Enhanced Research Quality for Disease Treatment

The imperative to advance research quality in structural biology is paramount for discovering treatments for diseases such as Cancer, Diabetes, and Alzheimer’s Disease. With the escalating challenges of drug resistance and high drug attrition rates, there is a growing demand for extensive R&D efforts. This surge in research activities is anticipated to drive the adoption of structural biology and molecular modeling techniques in the drug discovery and development process. By leveraging these advanced methodologies, the development of drugs with heightened potency can be expedited, thereby fueling the growth of the structural biology market.

Restraint

Challenges in Biological Machines

The intricacies of unraveling how biological machines function pose significant challenges in modern Biology. These machines consist of intricate networks of competing interactions that dynamically form and disassemble over time. Of increasing concern is the impact of post-translational modifications on protein structure and interaction modulation. The evolution of increased complexity in essential molecular machines often occurs through simple, high-probability evolutionary processes, without the apparent emergence of novel functions. Such findings suggest a plausible mechanism for the evolution of complexity in other multi-paralogue protein complexes, thereby presenting constraints on the growth of the structural biology market.

Opportunity

Structural Biology through Multidisciplinary Advancements

Structural biology stands poised to capitalize on interdisciplinary insights, drawing from fields like developmental, systems, and cell biology, as well as physics, information theory, computational sciences, and complex systems science. Technological strides, particularly driven by structural genomics consortia, have propelled the field forward, aiming to elucidate the 3D structure of every protein within a genome. Over the past decade, instrumental and software advancements have ushered in a "resolution revolution" in cryo-EM, enabling studies with resolutions akin to X-ray crystallography and expanding to investigations within intact cells. These methodological breakthroughs have transformed structural biology into a multidimensional and multimodal approach, integrating diverse techniques synergistically. This evolution presents ample opportunities for growth and innovation within the structural biology market.

  • In August 2023, the New York Structural Biology Center and Syncell announced a partnership for microscopy-guided proteomics.

Recent Developments

  • In August 2022, Constructive Bio launched with a $15m seed investment to re-engineer biology, creating new classes of enzymes, pharmaceuticals, and biomaterials
  • In April 2023, Bruker advanced its NMR Magnet Portfolio and innovated in industrial solutions
  • In July 2022, Cadence expanded into molecular simulation with the acquisition of OpenEye Scientific, a pioneering leader in computational molecular design
  • In May 2023, Recursion entered into agreements to acquire Cyclica and Valence to bolster chemistry and generative AI capabilities
  • In January 2022, Schrödinger announced the acquisition of XTAL BioStructures, Inc.
  • In November 2023, Ashoka University partnered with Carl Zeiss India to establish a state-of-the-art 'Core Imaging Facility'

Key Players in the Structural Biology Market

  • BiosolveIT GmbH
  • Thermo Fisher Scientific Inc.
  • Dassault Systemes
  • Optibrium Ltd.
  • Schrodinger
  • OpenEye Scientific Software, Inc.
  • Chemical Computing Group
  • Certara, L.P.
  • Cresset BioMolecular Discovery Ltd.
  • Acellera Ltd.
  • CGV S.A.
  • Simulations Plus, Inc.

Market Segmentation

  • By Tools
    • o SaaS and Standalone Modeling
    • o Visualization and Analysis
    • o Others
  • By Application
    • o Drug Development
    • o Drug Discovery
    • o Others
  • By Geography
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East and Africa

Get full access of this report@ https://www.precedenceresearch.com/checkout/3226 

Contact Us

Call: USA: +1 650 460 3308 | IND: +91 87933 22019 | Europe: +44 2080772818

Email: sales@precedenceresearch.com

Back to news